Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2598858 | 0.92 | MET (0.59) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL1331578 | 0.88 | MET (0.70) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL2570437 | 0.83 | MET (0.68) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL21172008 | 0.81 | MET (0.61) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL12122110 | 0.80 | MET (0.66) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL1330120 | 0.80 | MET (0.80) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL3424770 | 0.80 | MET (0.69) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL3409321 | 0.80 | MET (0.64) | METPDE3BPDE3A | |
| SCHEMBL1329272 | 0.79 | MET (0.56) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL1330543 | 0.79 | MET (0.56) | METCYP2C9PDE3BPDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912331-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-12-16 | — | — | US | claimed |
| US-20130261116-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2013-10-03 | — | — | US | claimed |
| EP-2571878-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | Incozen Therapeutics Pvt. Ltd. (IN) | 2013-03-27 | — | — | EP | claimed |
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2011-11-17 | — | — | US | claimed |
| CN-107674073-B | 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridine compounds as modulators of protein kinases | 印蔻真治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-17 | — | — | US | disclosed |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-17 | — | — | US | disclosed |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| EP-2571878-B1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INCOZEN THERAPEUTICS PVT LTD (IN) | 2018-10-17 | — | — | EP | disclosed |
| US-10087182-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2018-10-02 | — | — | US | disclosed |
| US-20170240542-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20150133449-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-8481739-B2 | 3,5-Disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H[1,2,3]triazolo [4,5-b] Pyridine Compounds as Modulators of protein kinases | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2013-07-09 | — | — | US | disclosed |
| EP-2571878-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | Incozen Therapeutics Pvt. Ltd. (IN) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MET 1570/4885CYP2C9 4369/4885PDE3B 542/4885 |
| US-20150133449-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MET 1570/4885CYP2C9 4369/4885PDE3B 542/4885 |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | MAP4K2, MAP3K3, MAP3K1 | MET 1142/4885CYP2C9 4463/4885PDE3B 524/4885 |
| US-20130261116-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MET 1570/4885CYP2C9 4369/4885PDE3B 542/4885 |
| US-20190218211-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MET 1570/4885CYP2C9 4369/4885PDE3B 542/4885 |
| US-10087182-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | MAP4K2, MAP3K3, MAP3K1 | MET 1142/4885CYP2C9 4463/4885PDE3B 524/4885 |
| US-20170240542-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MET 1570/4885CYP2C9 4369/4885PDE3B 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.